Preclinical Development of BI-1206 -Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy
Time: 2:15 pm
day: Conference Day One
Details:
- Unveiling the development of a PDX-model that recapitulates relapsed/refractory disease
- Highlighting the importance of a relevant tolerability model for successful clinical development
